Results 101 to 110 of about 20,209,781 (300)

Modulation of the innate immune response by Yersinia enterocolitica upon systemic infection [PDF]

open access: yes, 2006
Yersinia enterocolitica causes acute and chronic enteric infections and complications such as septicaemia or reactive arthritis. The survival strategy of Y.
Matteoli, Gianluca
core   +1 more source

Innate immune defence to Campylobacter jejuni. [PDF]

open access: yes, 2007
Campylobacter jejuni is the most prevalent cause of bacterial diarrhoea worldwide and is frequently associated with severe post-infectious complications such as the Guillain-Barre syndrome.
Zilbauer, Matthias, Zilbauer, M.
core  

The influence of viral RNA secondary structure on interactions with innate host cell defences [PDF]

open access: yes, 2013
RNA viruses infecting vertebrates differ fundamentally in their ability to establish persistent infections with markedly different patterns of transmission, disease mechanisms and evolutionary relationships with their hosts.
Blundell, Richard   +14 more
core   +1 more source

Profiling neoadjuvant therapy response in rectal cancer using meta‐analysis of publicly available transcriptomic RNA‐seq datasets

open access: yesMolecular Oncology, EarlyView.
This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic   +10 more
wiley   +1 more source

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

open access: yesMolecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira   +7 more
wiley   +1 more source

RELATIONSHIP BETWEEN THE INNATE AND ADAPTIVE IMMUNITY IN INFECTIONS (REVISION OF CLASSIC DOGMA)

open access: yesИнфекция и иммунитет, 2014
. The mechanisms of the immune system responding to an infection depend on a complex interrelation between the elements of innate and adaptive immunity. The current understanding of how signaling from innate immunity receptors shapes the adaptive immune ...
I. S. Freidlin
doaj   +1 more source

Potential candidate genes of Dj-BS innate immune system.

open access: yes, 2016
Potential candidate genes of Dj-BS innate immune system.
Xiaowen Sun (172452)   +9 more
core   +1 more source

Alterations in early cytokine-mediated immune responses to Plasmodium falciparum infection in Tanzanian children with mineral element deficiencies: a cross-sectional survey. [PDF]

open access: yes, 2010
BACKGROUND: Deficiencies in vitamins and mineral elements are important causes of morbidity in developing countries, possibly because they lead to defective immune responses to infection.
Veenemans, J.   +35 more
core   +1 more source

APOBEC3 activity and DNA polymerase‐ε deficiency are associated with distinct IDH1 R132 hotspot mutations

open access: yesMolecular Oncology, EarlyView.
Isocitrate dehydrogenase 1 (IDH1) mutations are highly recurrent in multiple human cancer types, including cholangiocarcinoma and glioma. IDH1 R132C is the most common IDH1 mutation in cholangiocarcinoma and likely arises from APOBEC3A‐ or APOBEC3B‐mediated deamination.
Kelly E. Butler   +3 more
wiley   +1 more source

The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant [PDF]

open access: yes, 2013
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a potent type I interferon (IFN) inducer, was evaluated as a chemotherapeutic agent in mouse cancer models and proved to be well tolerated in human cancer clinical trials.
Cevayir Coban   +35 more
core   +1 more source

Home - About - Disclaimer - Privacy